CRBP
Companies
NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Health Care
$8.28
-$3.49 (-29.58%)
Price Chart
Overview
About CRBP
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Market Cap
$471.6M
Volume
940.9K
Avg. Volume
1.3M
P/E Ratio
-1.4007634
Dividend Yield
0.00%
Employees
35.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.75
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CRBP shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$471.6M
Volume940.9K
P/E Ratio-1.40
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 6, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025